Before beginning a NAD+ prescription or infusion, ask how the care team handles symptoms during treatment and after you leave the clinic or receive a shipment. A clear contact plan is more useful than a promise that a product has no side effects.
Risk depends on the person, preparation, route, and care setting. This guide does not provide a complete list of possible reactions or determine whether a product is safe for you. Your prescriber should review your history, medications, and the proposed preparation.
Know how to reach care before starting. Significant reactions need assessment, and tolerability alone does not establish benefit.
Take significant symptoms seriously
The FDA has received reports of severe chills, shaking, vomiting, and fatigue following NAD+ injectables, with some people needing medical treatment. The notice relates to concerns about unsuitable ingredients and endotoxins; it does not establish a reaction rate for every provider.
Do not describe a severe reaction as a normal “detox” or proof of benefit. For trouble breathing, chest pain, fainting, or rapidly worsening symptoms, seek emergency medical help. If you are in the US and need emergency assistance, call 911. Do not wait for a review website or a routine portal reply.
For skin warmth or redness, read flushing and niacin. For products used with prescriptions, use the medication-interaction guide to prepare a full-label review.
Clarify the routine and urgent contacts
Before treatment, record the clinician’s contact, the dispensing pharmacy’s number, and any after-hours instructions. Ask which concerns should go to the pharmacist, which need a clinical assessment, and which require urgent care.
For an infusion, ask how staff monitor symptoms and who can make clinical decisions during the visit. For a home prescription, ask what you should do if a symptom occurs between scheduled check-ins. The answers should be specific to your plan, rather than copied from another person’s experience.
Make a useful record
If a problem occurs, record the product name, pharmacy, lot information, date and time of use, what you noticed, and other relevant medicines or supplements. Preserve the label and packaging. Share this information with the care team without delaying urgent treatment.
Do not try to troubleshoot a suspected reaction by changing the dose, adding another substance, or changing the route on your own. Ask the prescriber about further use. The prescription-label guide explains why concentration and device details matter when describing what was supplied.
Discuss your health history before approval
Tell the clinician about ongoing conditions, allergies, prior reactions, current medicines, and any other NAD-related products. Mention pregnancy, breastfeeding, or plans for pregnancy when relevant. Do not assume a broad online questionnaire captured every concern you intended to raise.
If you are seeking help for new or persistent fatigue, ask whether that symptom needs evaluation independently of a wellness treatment. Our appointment checklist helps you describe the concern and identify the information you still need.
Reassess benefit as well as tolerance
Tolerating a product does not prove that it is useful. Arrange a follow-up to discuss meaningful changes, unwanted effects, the burden of the routine, and cost. A decision to stop or investigate another cause can be a reasonable outcome of that discussion.
Read the evidence guide alongside this safety discussion. The available studies we reviewed do not establish that every route and finished product has the same safety or benefit profile. A commercial ranking should not replace this individual assessment.
Supplements, sprays, and symptoms lasting after use.
Adverse effects depend on the route and complete formula. An oral blend may add caffeine, niacin forms, botanicals, or other ingredients; compare supplement labels rather than assuming every product is NAD alone. Nasal sprays and patches raise local irritation and handling questions. There is no universal duration after which a reaction is safe to ignore. Persistent or worsening symptoms need clinical advice; serious symptoms need urgent assessment. Also review pregnancy and other safety questions and cancer-related evidence.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- FDA: ingredients suitable for sterile compounding Safety notice describing reported reactions and ingredient-quality concerns.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
- Reyna et al. (2026): retrospective IV tolerability pilot Route-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.